Although anti-tumor necrosis factor (TNF) therapy has revo-lutionised the management of spondyloarthritis (SpA), 20–30% of SpA patients discontinue biological treatment because they fail to respond or their response is inadequate, and 10–20% stop because of a lack or loss of efficacy or the onset of adverse events. Published data show that anti-TNF drugs in are highly effective in patients with ankylosing spondylitis, and associated with a higher drug persistence rate. Furthermore, studies suggest considering a switch to another anti-TNF drug if a first anti-TNF agent is discontinued because of loss of efficacy or adverse events.
Ankylosing Spondylitis Treatment after First Anti-TNF Drug Failure / M. Benucci, A. Damiani, F. Bandinelli, V. Grossi, M. Infantino, M. Manfredi, F.L. Gobbi, P. Sarzi-Puttini, F. Atzeni. - In: ISRAEL MEDICAL ASSOCIATION JOURNAL. - ISSN 1565-1088. - 20:2(2018 Feb), pp. 119-122.
Titolo: | Ankylosing Spondylitis Treatment after First Anti-TNF Drug Failure |
Autori: | |
Parole Chiave: | ankylosing spondylitis (AS); anti-tumor necrosis factor (anti-TNF) drugs; efficacy; adverse events |
Settore Scientifico Disciplinare: | Settore MED/16 - Reumatologia |
Data di pubblicazione: | feb-2018 |
Rivista: | |
URL: | https://www.ima.org.il/FilesUpload/IMAJ/0/272/136247.pdf |
Tipologia: | Article (author) |
Appare nelle tipologie: | 01 - Articolo su periodico |
File in questo prodotto:
File | Descrizione | Tipologia | Licenza | |
---|---|---|---|---|
136247.pdf | Publisher's version/PDF | Open Access Visualizza/Apri |